Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol.
<h4>Background</h4>Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma subtype with a significant relapse rate and poor prognosis in relapsed/refractory (R/R) patients. Polatuzumab vedotin in combination with bendamustine and rituximab (Pola-BR) has demonstrated p...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0308247 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586222465187840 |
|---|---|
| author | Mohammadreza Eslami Mahdi Mehrabi Mehrdad Payandeh Fakhredin Saba |
| author_facet | Mohammadreza Eslami Mahdi Mehrabi Mehrdad Payandeh Fakhredin Saba |
| author_sort | Mohammadreza Eslami |
| collection | DOAJ |
| description | <h4>Background</h4>Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma subtype with a significant relapse rate and poor prognosis in relapsed/refractory (R/R) patients. Polatuzumab vedotin in combination with bendamustine and rituximab (Pola-BR) has demonstrated promising efficacy and safety as salvage therapy for R/R DLBCL. This systematic review protocol aims to comprehensively evaluate the efficacy of Pola-BR for the treatment of R/R DLBCL by synthesizing data from relevant randomized controlled trials.<h4>Methods</h4>This protocol details the eligibility criteria, search strategy, study selection, data extraction, and analysis methods for the systematic review. Randomized controlled trials comparing Pola-BR with other interventions for R/R DLBCL will be included. The primary endpoint is overall survival, with secondary endpoints being progression-free survival and incidence of adverse events. A comprehensive search will be conducted across databases such as Medline/PubMed, Cochrane Library, Web of Science, Scopus, EMBASE, ProQuest, EU Clinical Trials Register, WHO International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov from the January 2000 to April 2024. To assess the potential risk of bias, the Cochrane Risk of Bias 1 tool will be used. Data synthesis will utilize fixed-effect or random-effects models, and subgroup and meta-regression analyses will examine heterogeneity. Additionally, publication bias and sensitivity analyses will be performed, and the GRADE approach will be applied to assess the certainty of the evidence.<h4>Conclusion</h4>This systematic review and meta-analysis protocol provides a rigorous framework for evaluating the efficacy of Pola-BR in the treatment of R/R DLBCL. The results will inform clinical decision-making and guideline development, addressing the unmet need for effective and tolerable treatments for this challenging patient population. Potential limitations and biases will be acknowledged, and future research directions will be discussed. |
| format | Article |
| id | doaj-art-c2252c08839d4115838980ee623584c3 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-c2252c08839d4115838980ee623584c32025-01-26T05:31:22ZengPublic Library of Science (PLoS)PLoS ONE1932-62032024-01-01198e030824710.1371/journal.pone.0308247Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol.Mohammadreza EslamiMahdi MehrabiMehrdad PayandehFakhredin Saba<h4>Background</h4>Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma subtype with a significant relapse rate and poor prognosis in relapsed/refractory (R/R) patients. Polatuzumab vedotin in combination with bendamustine and rituximab (Pola-BR) has demonstrated promising efficacy and safety as salvage therapy for R/R DLBCL. This systematic review protocol aims to comprehensively evaluate the efficacy of Pola-BR for the treatment of R/R DLBCL by synthesizing data from relevant randomized controlled trials.<h4>Methods</h4>This protocol details the eligibility criteria, search strategy, study selection, data extraction, and analysis methods for the systematic review. Randomized controlled trials comparing Pola-BR with other interventions for R/R DLBCL will be included. The primary endpoint is overall survival, with secondary endpoints being progression-free survival and incidence of adverse events. A comprehensive search will be conducted across databases such as Medline/PubMed, Cochrane Library, Web of Science, Scopus, EMBASE, ProQuest, EU Clinical Trials Register, WHO International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov from the January 2000 to April 2024. To assess the potential risk of bias, the Cochrane Risk of Bias 1 tool will be used. Data synthesis will utilize fixed-effect or random-effects models, and subgroup and meta-regression analyses will examine heterogeneity. Additionally, publication bias and sensitivity analyses will be performed, and the GRADE approach will be applied to assess the certainty of the evidence.<h4>Conclusion</h4>This systematic review and meta-analysis protocol provides a rigorous framework for evaluating the efficacy of Pola-BR in the treatment of R/R DLBCL. The results will inform clinical decision-making and guideline development, addressing the unmet need for effective and tolerable treatments for this challenging patient population. Potential limitations and biases will be acknowledged, and future research directions will be discussed.https://doi.org/10.1371/journal.pone.0308247 |
| spellingShingle | Mohammadreza Eslami Mahdi Mehrabi Mehrdad Payandeh Fakhredin Saba Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol. PLoS ONE |
| title | Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol. |
| title_full | Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol. |
| title_fullStr | Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol. |
| title_full_unstemmed | Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol. |
| title_short | Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol. |
| title_sort | polatuzumab vedotin combined with bendamustine and rituximab for relapsed refractory diffuse large b cell lymphoma a systematic review protocol |
| url | https://doi.org/10.1371/journal.pone.0308247 |
| work_keys_str_mv | AT mohammadrezaeslami polatuzumabvedotincombinedwithbendamustineandrituximabforrelapsedrefractorydiffuselargebcelllymphomaasystematicreviewprotocol AT mahdimehrabi polatuzumabvedotincombinedwithbendamustineandrituximabforrelapsedrefractorydiffuselargebcelllymphomaasystematicreviewprotocol AT mehrdadpayandeh polatuzumabvedotincombinedwithbendamustineandrituximabforrelapsedrefractorydiffuselargebcelllymphomaasystematicreviewprotocol AT fakhredinsaba polatuzumabvedotincombinedwithbendamustineandrituximabforrelapsedrefractorydiffuselargebcelllymphomaasystematicreviewprotocol |